Ocular immunology and inflammation · 2013
Long-term clinical outcomes in patients with refractory uveitis associated with Behçet disease treated with infliximab.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Al Rashidi Sultan, Al Fawaz Abdullah, Kangave Dustan, Abu El-Asrar Ahmed M
Аннотация
PURPOSE: To assess long-term efficacy and safety of infliximab for refractory Behçet disease (BD) uveitis and to evaluate the effect of withdrawal of infliximab after achieving long-term remission.
METHODS: Retrospective study of 19 patients.
RESULTS: Mean follow-up was 44.1 ± 36.5 months and mean number of infliximab infusions was 21.6 ± 14.6. At end of follow-up, there was significant improvement of visual acuity and reduction of central macular thickness. All patients achieved remission, 14 of whom were able to discontinue corticosteroids. Ten patients developed autoantibodies and 1 patient developed infusion reactions. Eight eyes underwent intraocular surgery without exacerbation of quiescent uveitis. After achieving complete remission, 5 patients discontinued infliximab and maintained remission during a mean of 24.6 ± 5.5 months.
CONCLUSIONS: Infliximab is effective and safe for long-term treatment for refractory BD uveitis. Repeated infusions are required to maintain long-term remission, which may be sustained despite withdrawal of infliximab. Induction of autoantibodies is common.
METHODS: Retrospective study of 19 patients.
RESULTS: Mean follow-up was 44.1 ± 36.5 months and mean number of infliximab infusions was 21.6 ± 14.6. At end of follow-up, there was significant improvement of visual acuity and reduction of central macular thickness. All patients achieved remission, 14 of whom were able to discontinue corticosteroids. Ten patients developed autoantibodies and 1 patient developed infusion reactions. Eight eyes underwent intraocular surgery without exacerbation of quiescent uveitis. After achieving complete remission, 5 patients discontinued infliximab and maintained remission during a mean of 24.6 ± 5.5 months.
CONCLUSIONS: Infliximab is effective and safe for long-term treatment for refractory BD uveitis. Repeated infusions are required to maintain long-term remission, which may be sustained despite withdrawal of infliximab. Induction of autoantibodies is common.
Предметные рубрики MeSH
AdolescentAdultAnti-Inflammatory Agents, Non-SteroidalAntibodies, MonoclonalBehcet SyndromeChildFemaleFluorescein AngiographyFollow-Up StudiesFundus OculiHumansInfliximabInfusions, IntravenousMaleRemission InductionRetrospective StudiesTime FactorsTomography, Optical CoherenceTreatment OutcomeTumor Necrosis Factor-alphaUveitis, PosteriorVisual AcuityYoung Adult